RayKnowChina Research Map
Shortlist

Guangzhou

Guangdong Provincial People's Hospital

广东省人民医院

Listed for 24 of the 53 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.

Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.

No official website checked for this hospital yet.

Getting in touch

Research at Guangdong Provincial People's Hospital

Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.

Only the 53 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed

  1. Nasopharyngeal carcinoma鼻咽癌14 papers led
  2. Oesophageal squamous cell carcinoma食管鳞状细胞癌19 papers led
  3. Hepatocellular carcinoma肝细胞癌54 papers led1 open trial led
  4. Stomach cancer胃癌21 papers led1 open trial led
  5. Hepatoblastoma肝母细胞瘤1 paper led
  6. Retinoblastoma视网膜母细胞瘤2 papers led
  7. Chordoma脊索瘤1 paper led
  8. Osteosarcoma骨肉瘤11 papers led
  9. Gastrointestinal stromal tumour胃肠道间质瘤1 paper led
  10. Neuroblastoma神经母细胞瘤0 papers led
  11. Multiple myeloma多发性骨髓瘤3 papers led
  12. B-cell acute lymphoblastic leukaemiaB 细胞急性淋巴细胞白血病1 paper led
  13. Beta thalassaemiaβ 地中海贫血1 paper led
  14. Neuromyelitis optica spectrum disorder视神经脊髓炎谱系疾病3 papers led
  15. IgG4-related diseaseIgG4相关性疾病3 papers led
  16. Myasthenia gravis重症肌无力1 paper led
  17. Takayasu arteritis大动脉炎0 papers led
  18. Idiopathic pulmonary fibrosis特发性肺纤维化2 papers led
  19. Amyotrophic lateral sclerosis肌萎缩侧索硬化症1 paper led
  20. Fabry disease法布雷病1 paper led
  21. Behçet disease白塞病1 paper led
  22. IgA nephropathyIgA 肾病8 papers led1 open trial led
  23. Primary biliary cholangitis原发性胆汁性胆管炎4 papers led
  24. Primary sclerosing cholangitis原发性硬化性胆管炎1 paper led

Not listed for: Ewing sarcoma, Aplastic anaemia, Haemophagocytic lymphohistiocytosis, Haemophilia A, Atypical haemolytic uraemic syndrome, Thrombotic thrombocytopenic purpura, Fanconi anaemia, Moyamoya disease, Wilson disease, Biliary atresia, Anti-NMDA receptor encephalitis, Hepatic echinococcosis, Lymphangioleiomyomatosis, Spinal muscular atrophy, Pompe disease, Duchenne muscular dystrophy, Alport syndrome, Gaucher disease, Niemann–Pick disease type C, Osteogenesis imperfecta, Congenital diaphragmatic hernia, Hirschsprung disease, Inherited epidermolysis bullosa, Hereditary angioedema, Familial adenomatous polyposis, Leber hereditary optic neuropathy, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.

Cancer

Nasopharyngeal carcinoma

鼻咽癌

Led 14 of the 2,375 English-language PubMed papers on nasopharyngeal carcinoma with an author in mainland China, 2021–2025: 0.6%.

Papers led
14
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
2
led by another institution
Papers led per year
2021: 1120212022: 1120222023: 4420232024: 1120242025: 772025

24 hospitals in Guangzhou for nasopharyngeal carcinoma183 hospitals in China for nasopharyngeal carcinoma

Open trials with this hospital 2

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Combination Therapy for PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Bayesian Adaptive Phase II Trial
    Phase
    Phase 2
    Started
    2025-06
    Registry
    NCT07070479

    Age 18 years to 70 years (registered criteria)

    Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesChangsha, Guangzhou, Zhongshan, Zhuhai

  2. Recruiting
    Effect of Immunonutrients on Oral Mucositis in Nasopharyngeal Carcinoma Patients After Chemoradiotherapy
    Phase
    N/A
    Started
    2023-06
    Registry
    NCT05892354

    Age 18 years to 70 years (registered criteria)

    Led by First Affiliated Hospital of Guangxi Medical University; 13 listed hospitals as study sitesFuzhou, Guangzhou, Guilin, Haikou, Hangzhou, Liuzhou, Nanchang, Nanning, Wuzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesRadiotherapy techniqueImaging & AIInduction / concurrent chemotherapy
Departments in papersENT / head & neck surgeryMedical oncologyRadiation oncologyRadiology / nuclear medicine
Papers it led14
  1. Chemoimmunotherapy as induction treatment in concurrent chemoradiotherapy for patients with nasopharyngeal carcinoma stage IVa.2025Annals of medicineFree full text
  2. Integrating pan-immune-inflammation value into personalized survival prediction of nasopharyngeal carcinoma: a large-scale long-term retrospective study.2025BMC cancerFree full text
  3. Efficacy and safety of induction immunotherapy plus chemotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: a meta-analysis.2025British journal of cancerFree full text
  4. Prediction of Recurrence using a Stacked Denoising Autoencoder and Multifaceted Feature Analysis of Pretreatment MRI in Patients with Nasopharyngeal Carcinoma.2025Current radiopharmaceuticals
  5. Cholesterol-to-lymphocyte ratio (CLR)-based nomogram as a prognostic tool in nasopharyngeal carcinoma: a large-scale long-term retrospective study.2025European journal of medical researchFree full text
  6. Application of Large Language Models in TN Staging and Treatment Response Evaluation for Patients With Nasopharyngeal Carcinoma: A Comparative Performance Analysis of ChatGPT-4o-Latest and DeepSeek-V3-0324.2025Journal of magnetic resonance imaging : JMRI
  7. Key Risk Factors for Postoperative Hypotension in Nasopharyngeal Carcinoma Patients After Endoscopic Surgery: A Retrospective Study.2025Medical science monitor : international medical journal of experimental and clinical researchFree full text
  8. ThermomiR-377-3p-induced suppression of Cirbp expression is required for effective elimination of cancer cells and cancer stem-like cells by hyperthermia.2024Journal of experimental & clinical cancer research : CRFree full text
  9. Enhancer remodeling activates NOTCH3 signaling to confer chemoresistance in advanced nasopharyngeal carcinoma.2023Cell death & diseaseFree full text
  10. A glutathione-sensitive cationic polymer delivery of CRISPR-Cas9 RNA plasmid for targeting nasopharyngeal carcinoma gene therapy.2023Colloids and surfaces. B, Biointerfaces
  11. Endoscopic surgery versus intensity-modulated radiotherapy in locally advanced recurrent nasopharyngeal carcinoma: a multicenter, case-matched comparison.2023Journal of otolaryngology - head & neck surgery = Le Journal d'oto-rhino-laryngologie et de chirurgie cervico-facialeFree full text
  12. Using the non-distortion IVIM to reduce the need for contrast agents in nasopharyngeal MRI.2023Magnetic resonance imaging
  13. Effects of combination docetaxel with NO treatment to enhance the anti-nasopharyngeal carcinoma efficiency in vitro and in vivo.2022European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
  14. Long-Term Outcomes of Cochlear Implantation in Irradiated Ears of Nasopharyngeal Carcinoma Patients.2021The Laryngoscope
Chinese-language papers (not in the count)1
  1. [Skull base defect reconstruction after surgery for recurrent nasopharyngeal carcinoma].2022Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of otorhinolaryngology head and neck surgery
All its trials on ClinicalTrials.gov, any status5
  1. Early Nutritional Intervention in NPC Patients Undergoing Concurrent ChemoradiotherapyStatus unknownNCT04810936Lead sponsorN/AStart 2019-07
  2. Combination Therapy for PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Bayesian Adaptive Phase II TrialRecruitingNCT07070479Study sitePhase 2Start 2025-06
  3. Effect of Immunonutrients on Oral Mucositis in Nasopharyngeal Carcinoma Patients After ChemoradiotherapyRecruitingNCT05892354Study siteN/AStart 2023-06
  4. Detection and Biopsy Guidance of Nasopharyngeal Carcinoma Based on Artificial Intelligence and Endoscopic ImagesStatus unknownNCT05202626Study siteStart 2021-12
  5. Tislelizumab Combined With Chemotherapy Versus Chemotherapy Alone in Recurrent or Metastatic Nasopharyngeal Cancer (NPC)CompletedNCT03924986Study sitePhase 3Start 2019-03
More papers found outside PubMed (not counted)10
  1. 1376P A comprehensive overview of immune-related adverse events induced by immune checkpoint inhibitors in nasopharyngeal carcinoma2025Annals of Oncologyarticle
  2. Efficacy and safety of induction chemoimmunotherapy versus induction chemotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: A meta-analysis.2025Journal of Clinical Oncologyarticle
  3. 402O Preliminary results of phase II study to evaluate safety and efficacy of combination pucotenlimab with epidermal growth factor receptor-ADC (EGFR-ADC) MRG003 in recurrent or metastatic nasopharyngeal carcinoma (R/M-NPC)2024Annals of Oncologyarticle
  4. 455P A real-world study: Induction chemoimmunotherapy versus induction chemotherapy followed by concurrent chemoradiotherapy in nasopharyngeal carcinoma patients with stage IVa2024Annals of Oncologyarticle
  5. Microplastics Antagonize the Therapeutic Effect of Curcumin on Nasopharyngeal Carcinoma Through Inhibiting the Apoptosis Pathway2024SSRN Electronic Journalpreprint
  6. SICNet: Learning selective inter-slice context via Mask-Guided Self-knowledge distillation for NPC segmentation2024Journal of Visual Communication and Image Representationarticle
  7. Enhanced Multi-Task Nasopharyngeal Carcinoma Recurrence Prediction by Knowledge Distillation with Loss-Balanced Weighting Strategy2023International Conference on Intelligent Computing and Human-Computer Interaction (ICHCI)conference-paper
  8. Risk Factors Analysis of Post Anesthesia Induction Hypotension in Patients with Recurrent Nasopharyngeal Carcinoma2023Journal of medicine and health science.article
  9. Additional file 1 of Comparing the efficacy and safety of cisplatin and other platinum-based chemotherapies in locally advanced nasopharyngeal carcinoma: a systematic review and meta-analysis2022Figsharereview
  10. Effect of Exercise on Sternoceleidomastoid Muscular Fibrosis after Radiotherapy for Nasopharyngeal Carcinoma Patients Analyzed by Shear-Wave Elastography2022Rehabilitation Medicinearticle

Run the PubMed searchClinicalTrials.gov

Cancer

Oesophageal squamous cell carcinoma

食管鳞状细胞癌

Led 19 of the 2,923 English-language PubMed papers on oesophageal squamous cell carcinoma with an author in mainland China, 2021–2025: 0.7%.

Papers led
19
2021–2025
Trials led
5
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 5520222023: 5520232024: 4420242025: 552025

11 hospitals in Guangzhou for oesophageal squamous cell carcinoma192 hospitals in China for oesophageal squamous cell carcinoma

No open trial on oesophageal squamous cell carcinoma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesImmunotherapyNeoadjuvant & combined treatmentMolecular markers & genomics
Departments in papersMedical oncologyRadiation oncologyRadiology / nuclear medicine
Papers it led19
  1. Association Between Treatment-Related Adverse Event Trajectory and Prognosis in Esophageal Cancer Receiving Neoadjuvant Immunochemotherapy.2025Annals of surgical oncology
  2. ISCU-p53 axis orchestrates macrophage polarization to dictate immunotherapy response in esophageal squamous cell carcinoma.2025Cell death & diseaseFree full text
  3. m6A-mediated circG3BP1 translocation to stress granules promotes nucleation and senescence-linked chemoresistance.2025Cell reports
  4. The mechanism of high mobility group box-1 in the proliferation and macrophage polarization in esophageal squamous cell carcinoma cells.2025European journal of medical researchFree full text
  5. Co-Infection by Porphyromonas gingivalis and Fusobacterium nucleatum Increases PD-L1 Expression in Esophageal Cancer Tissues.2025MicrobiologyOpenFree full text
  6. Decoding tumor stage by peritumoral and intratumoral radiomics in resectable esophageal squamous cell carcinoma.2024Abdominal radiology (New York)Free full text
  7. ASO Author Reflections: Enhancing Treatment Outcomes in Unresectable Esophageal Squamous Cell Carcinoma Through Immunochemotherapy.2024Annals of surgical oncology
  8. Induction Immunochemotherapy Yields a Higher Conversion Rate and Better Overall Survival than Chemotherapy in Initially Unresectable Esophageal Squamous Cell Carcinoma.2024Annals of surgical oncology
  9. Lymphatic endothelial cell-mediated accumulation of CD177+Treg cells suppresses antitumor immunity in human esophageal squamous cell carcinoma.2024OncoimmunologyFree full text
  10. Early and Persistent Dysphagia Relief Predicts Tumor Response in Esophageal Squamous Cell Carcinoma Patients Treated with Immunochemotherapy.2023Annals of surgical oncology
  11. PLEK2 and IFI6, representing mesenchymal and immune-suppressive microenvironment, predicts resistance to neoadjuvant immunotherapy in esophageal squamous cell carcinoma.2023Cancer immunology, immunotherapy : CIIFree full text
  12. Dissecting T-cell heterogeneity in esophageal squamous cell carcinoma reveals the potential role of LAIR2 in antitumor immunity.2023Clinical and experimental immunology
  13. Evidence on Effectiveness of Immune Checkpoint Inhibitors in Patients With Advanced Esophageal Squamous Cell Carcinoma.2023JAMA oncology
  14. COL19A1 is a predictive biomarker for the responsiveness of esophageal squamous cell carcinoma patients to immune checkpoint therapy.2023Thoracic cancerFree full text
  15. Comment on: "Is Adjuvant Therapy a Better Option for Esophageal Squamous Cell Carcinoma Patients Treated With Esophagectomy? A Prognosis Prediction Model Based on Multicenter Real-world Data".2022Annals of surgery
  16. Prediction of Individual Lymph Node Metastatic Status in Esophageal Squamous Cell Carcinoma Using Routine Computed Tomography Imaging: Comparison of Size-Based Measurements and Radiomics-Based Models.2022Annals of surgical oncology
  17. Predictive value of the presence of Prevotella and the ratio of Porphyromonas gingivalis to Prevotella in saliva for esophageal squamous cell carcinoma.2022Frontiers in cellular and infection microbiologyFree full text
  18. Conversion Surgery Following Immunochemotherapy in Initially Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma-A Real-World Multicenter Study (RICE-Retro).2022Frontiers in immunologyFree full text
  19. Assessment of durable chemoimmunotherapy response via circulating tumor DNA in advanced esophageal squamous cell carcinoma.2022Thoracic cancerFree full text
All its trials on ClinicalTrials.gov, any status7
  1. Efficacy Evaluation and Recurrence Monitoring of Therapy for Esophageal Squamous Cell Carcinoma Based on ctDNA-MRD.Status unknownNCT05900583Lead sponsorStart 2023-06
  2. Trajectory Analysis of NLR and Its Association With Efficacy of Immunochemotherapy in ESCC.Status unknownNCT06125262Lead sponsorStart 2022-11
  3. The PET-CT Predicting Response to Immunochemotherapy in Esophageal CancerStatus unknownNCT05615103Lead sponsorStart 2022-11
  4. Patient-reported Outcomes in Preoperative Immunochemotherapy/Radiotherapy-treated Esophageal Cancer PatientsStatus unknownNCT05596890Lead sponsorPhase 2Start 2022-11
  5. Sequence and Time-of-day Infusion of immunoCHemotherapy Affect Response in Oesophageal Cancer in the NeOadjuvant SettingCompletedNCT05615129Lead sponsorStart 2021-10
  6. A Study of SGN-B6A in Chinese Participants With Advanced Solid TumorsCompletedNCT06549816Study sitePhase 1Start 2024-08
  7. A Study of CS1001 in Subjects With Esophageal Squamous Cell CarcinomaCompletedNCT04187352Study sitePhase 3Start 2019-12
More papers found outside PubMed (not counted)19
  1. Alternative dosing regimens of tislelizumab proposed using modeling and simulation.2025Journal of Clinical Oncologyconference-abstract
  2. 418P A PET/CT image-based deep learning approach for precise survival prognosis and clinical management of treatments in patients with esophageal carcinoma2024Annals of Oncologyarticle
  3. 593. DEEP LEARNING-BASED PROGNOSTIC MODEL INTEGRATING TUMOR-INFILTRATING LYMPHOCYTES FOR ESOPHAGEAL CANCER: A MULTICENTER RETROSPECTIVE COHORT STUDY2024Diseases of the Esophagusarticle
  4. MO57-3 Effect of immunochemotherapy time-of-day infusion, sequence and interval on prognosis of advanced esophageal cancer2024Annals of Oncologyarticle
  5. 367. SPATIAL ORGANIZATION OF TUMOR-INFILTRATING LYMPHOCYTES PREDICTS PROGNOSIS OF PATIENTS WITH ESOPHAGEAL CANCER RECEIVING IMMUNOTHERAPY—A DEEP-LEARNING APPROACH2023Diseases of the Esophagusarticle
  6. Additional file 1 of Hypoxia-induced TMTC3 expression in esophageal squamous cell carcinoma potentiates tumor angiogenesis through Rho GTPase/STAT3/VEGFA pathway2023Figsharedataset
  7. Additional file 2 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma2023Figsharedataset
  8. Additional file 3 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma2023Figsharedataset
  9. Additional file 4 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma2023Figsharedataset
  10. Additional file 5 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma2023Figsharedataset
  11. Comparison of efficacy and safety of neoadjuvant regimens for resectable esophageal squamous cell carcinoma: A meta-analysis.2023Journal of Clinical Oncologyconference-abstract
  12. Identification of secretory factors associated with suppressive tumor microenvironment in esophageal cancer2023Research Squarepreprint
  13. Induction immunochemotherapy conversion rate and survival outcomes versus chemotherapy in initially unresectable esophageal squamous cell carcinoma.2023Journal of Clinical Oncologyconference-abstract
  14. Influence of high COL19A1 expression on the effectiveness of neoadjuvant immunotherapy plus chemotherapy and long-term survival in patients with esophageal squamous cell carcinoma.2023Journal of Clinical Oncologyconference-abstract
  15. Conversion surgery following immuno-chemotherapy in initially-unresectable esophageal squamous cell carcinoma: A real-world multicenter study.2022Journal of Clinical Oncologyconference-abstract
  16. One-day preoperative systemic treatment regimen outcompetes five-day regimen in potentially resectable esophageal squamous cancer2022medRxivpreprint
  17. 190P Transcriptomic molecular subtypes of esophageal squamous cell carcinoma predicted the prognosis and efficacy of neo-adjuvant immunotherapy2021Annals of Oncologyarticle
  18. Analysis of DNA damage response gene signature for prognosis prediction of esophageal squamous cell carcinoma.2021Journal of Clinical Oncologyconference-abstract
  19. First-line pembrolizumab plus chemotherapy versus chemotherapy in patients with advanced esophageal cancer: Chinese subgroup analysis of KEYNOTE-590.2021Journal of Clinical Oncologyconference-abstract

Run the PubMed searchClinicalTrials.gov

Cancer

Hepatocellular carcinoma

肝细胞癌

Led 54 of the 14,765 English-language PubMed papers on hepatocellular carcinoma with an author in mainland China, 2021–2025: 0.4%.

Papers led
54
2021–2025
Trials led
4
any status, ClinicalTrials.gov
Open trials led
1
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 8820212022: 9920222023: 9920232024: 131320242025: 13132025

15 hospitals in Guangzhou for hepatocellular carcinoma194 hospitals in China for hepatocellular carcinoma

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Lenvatinib, Tislelizumab Combined With RALOX Regimen HAIC in Advanced Hepatocellular Carcinoma
    Phase
    Phase 2
    Started
    2023-09
    Registry
    NCT05954897

    Age 18 years to Not stated (registered criteria)

    Led by Guangdong Provincial People's HospitalGuangzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesImmunotherapy & targeted drugsRecurrence & prognosisImaging, AI & early detection
Departments in papersSurgery (general/hepatobiliary/pancreatic)Radiology / nuclear medicineGastroenterology / hepatologyPathology / laboratory medicine

Over half of these papers are lab or animal studies.

Papers it led54
  1. Laminin β1 stimulates the Hippo-YAP1 pathway to advance the progression and lenvatinib resistance in hepatocellular carcinoma.2026International journal of biological macromolecules
  2. Mechanism of d-Glucaro-1,4-lactone enhancing the anticancer efficacy of lenvatinib via the IFN-γ-STAT3-PD-L1 signaling pathway in hepatocellular carcinoma.2026Phytomedicine : international journal of phytotherapy and phytopharmacology
  3. Liver diseases, transaminases, and hepatobiliary-pancreatic cancer risk: a cohort and Mendelian randomisation study using data from UK Biobank.2025BMJ open gastroenterologyFree full text
  4. AKR1D1 suppresses liver cancer progression by promoting bile acid metabolism-mediated NK cell cytotoxicity.2025Cell metabolism
  5. DTX2 attenuates Lenvatinib-induced ferroptosis by suppressing docosahexaenoic acid biosynthesis through HSD17B4-dependent peroxisomal β-oxidation in hepatocellular carcinoma.2025Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy
  6. Development and validation of interpretable machine learning model for pre-treatment predicting the response to targeted and immune therapy in hepatocellular carcinoma.2025European journal of radiology
  7. Comprehensive analysis of publications concerning combinations of immunotherapy and targeted therapies for hepatocellular carcinoma: a bibliometric study.2025Frontiers in immunologyFree full text
  8. Anti-Hepatocellular Carcinoma Effect of Jianpi Huayu Formula: Revealing the Molecular Mechanisms of the CXCR4 - Smad2/3 Pathway in Regulating Vasculogenic Mimicry Formation and Epithelial-Mesenchymal Transition.2025Integrative cancer therapiesFree full text
  9. Development of glypican-3-specific chimeric antigen receptor-modified natural killer cells and optimization as a therapy for hepatocellular carcinoma.2025Journal of leukocyte biology
  10. ENO1-BACE2-mediated LDLR cleavage promotes liver cancer progression by remodelling cholesterol metabolism.2025Journal of molecular cell biologyFree full text
  11. Histidine metabolism drives liver cancer progression via immune microenvironment modulation through metabolic reprogramming.2025Journal of translational medicineFree full text
  12. TPX2 lactylation is required for the cell cycle regulation and hepatocellular carcinoma progression.2025Life science allianceFree full text
  13. Transcriptomic analysis reveals the potential role of TOE1 in hepatocellular carcinoma.2025Scientific reportsFree full text
  14. Near-Infrared II Fluorescence Imaging Highlights Tumor Angiogenesis in Hepatocellular Carcinoma with a VEGFR-Targeted Probe.2025Small methods
  15. Predicting prognosis, immune landscape, and drug targets with a novel signature for hepatocellular carcinoma.2025Technology and health care : official journal of the European Society for Engineering and Medicine
  16. Impact of prior SARS-CoV-2 infection on postoperative recovery in patients with hepatocellular carcinoma resection.2024BMC gastroenterologyFree full text
  17. Quercetin-induced degradation of RhoC suppresses hepatocellular carcinoma invasion and metastasis.2024Cancer medicine
  18. Moderate expression of CD39 in GPC3-CAR-T cells shows high efficacy against hepatocellular carcinoma.2024Frontiers of medicine
  19. A commentary on 'Laparoscopic anatomical versus non-anatomical hepatectomy in the treatment of hepatocellular carcinoma: a randomised controlled trial'.2024International journal of surgery (London, England)Free full text
  20. Commentary on 'Liver resection versus transarterial chemoembolisation for the treatment of intermediate hepatocellular carcinoma: a systematic review and meta-analysis'.2024International journal of surgery (London, England)Free full text
  21. Prognostic model for unresectable hepatocellular carcinoma treated with dual PD-1 and angiogenesis blockade therapy.2024Journal for immunotherapy of cancerFree full text
  22. Mechanistic insights into xanthomicrol as the active anti-HCC ingredient of Phytolacca acinosa Roxb.: A network pharmacology analysis and transcriptomics integrated experimental verification.2024Journal of ethnopharmacology
  23. Targeting OXCT1-mediated ketone metabolism reprograms macrophages to promote antitumor immunity via CD8+ T cells in hepatocellular carcinoma.2024Journal of hepatology
  24. Adverse clinical outcomes and immunosuppressive microenvironment of RHO-GTPase activation pattern in hepatocellular carcinoma.2024Journal of translational medicineFree full text
  25. Citrullination modulation stabilizes HIF-1α to promote tumour progression.2024Nature communicationsFree full text
  26. HKDC1 promotes tumor immune evasion in hepatocellular carcinoma by coupling cytoskeleton to STAT1 activation and PD-L1 expression.2024Nature communicationsFree full text
  27. Carnosine regulation of intracellular pH homeostasis promotes lysosome-dependent tumor immunoevasion.2024Nature immunology
  28. EPDR1 promotes PD-L1 expression and tumor immune evasion by inhibiting TRIM21-dependent ubiquitylation of IkappaB kinase-β.2024The EMBO journalFree full text
  29. The genetic liability to rheumatoid arthritis may decrease hepatocellular carcinoma risk in East Asian population: a Mendelian randomization study.2023Arthritis research & therapyFree full text
  30. Identification of therapeutic targets and prognostic biomarkers among CXC chemokines in hepatocellular carcinoma microenvironment.2023Cancer biomarkers : section A of Disease markersFree full text
  31. Peripheral Th and NK cells are associated with response to lenvatinib plus PD-1 inhibitor in unresectable hepatocellular carcinoma.2023Clinical immunology (Orlando, Fla.)
  32. Characterization of heterogeneous metabolism in hepatocellular carcinoma identifies new therapeutic target and treatment strategy.2023Frontiers in immunologyFree full text
  33. All-trans-retinoic acid inhibits hepatocellular carcinoma progression by targeting myeloid-derived suppressor cells and inhibiting angiogenesis.2023International immunopharmacology
  34. Molecular phenotypic linkage between N6-methyladenosine methylation and tumor immune microenvironment in hepatocellular carcinoma.2023Journal of cancer research and clinical oncologyFree full text
  35. CircFOXK2 promotes hepatocellular carcinoma progression and leads to a poor clinical prognosis via regulating the Warburg effect.2023Journal of experimental & clinical cancer research : CRFree full text
  36. Itaconate promotes hepatocellular carcinoma progression by epigenetic induction of CD8+ T-cell exhaustion.2023Nature communicationsFree full text
  37. Conversion surgery for advanced hepatocellular carcinoma after combination treatment of lenvatinib and camrelizumab: a case report.2023World journal of surgical oncologyFree full text
  38. Albumin-Bilirubin Score to Predict Outcomes in Patients with Idiopathic Dilated Cardiomyopathy.2022Arquivos brasileiros de cardiologiaFree full text
  39. Circular RNA CircITCH (has-circ-0001141) suppresses hepatocellular carcinoma (HCC) progression by sponging miR-184.2022Cell cycle (Georgetown, Tex.)Free full text
  40. Branched-chain amino acid catabolism breaks glutamine addiction to sustain hepatocellular carcinoma progression.2022Cell reports
  41. A Pyroptosis-Based Prognostic Model for Immune Microenvironment Estimation of Hepatocellular Carcinoma.2022Disease markersFree full text
  42. Preoperative prediction of intra-tumoral tertiary lymphoid structures based on CT in hepatocellular cancer.2022European journal of radiology
  43. Genome-Wide CRISPR/Cas9 Library Screening Identified that DUSP4 Deficiency Induces Lenvatinib Resistance in Hepatocellular Carcinoma.2022International journal of biological sciencesFree full text
  44. An injectable thermosensitive hydrogel loaded with a theranostic nanoprobe for synergistic chemo-photothermal therapy for multidrug-resistant hepatocellular carcinoma.2022Journal of materials chemistry. B
  45. Myeloid-derived suppressor cells promote tumor growth and sorafenib resistance by inducing FGF1 upregulation and fibrosis.2022Neoplasia (New York, N.Y.)Free full text
  46. Immune checkpoint inhibitor therapy for malignant tumors in liver transplantation recipients: A systematic review of the literature.2022Transplantation reviews (Orlando, Fla.)
  47. Prediction of Microvascular Invasion of Hepatocellular Carcinoma Based on Preoperative Diffusion-Weighted MR Using Deep Learning.2021Academic radiology
  48. Predictive value of a novel lncRNA LINC02518 in evaluating the prognosis of patients with hepatocellular carcinoma.2021Biomarkers in medicine
  49. Prognosis and personalized treatment prediction in TP53-mutant hepatocellular carcinoma: an in silico strategy towards precision oncology.2021Briefings in bioinformatics
  50. HBO1 overexpression is important for hepatocellular carcinoma cell growth.2021Cell death & diseaseFree full text
  51. Association between hepatitis B and E virus infection and hepatocellular carcinoma risk.2021International journal of cancer
  52. Clinicopathological and prognostic value of preoperative lymphocyte to monocyte ratio for hepatocellular carcinoma following curative resection: A meta-analysis including 4,092 patients.2021MedicineFree full text
  53. DNase1L3 suppresses hepatocellular carcinoma growth via inhibiting complement autocrine effect.2021Neoplasma
  54. miR-4454 Promotes Hepatic Carcinoma Progression by Targeting Vps4A and Rab27A.2021Oxidative medicine and cellular longevityFree full text
Chinese-language papers (not in the count)4
  1. Identification of prognosis-related key genes in hepatocellular carcinoma based on bioinformatics analysis.2025Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciencesFree full text
  2. [Research progress of radiomics in hepatocellular carcinoma].2024Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatologyFree full text
  3. [Fontan-associated liver disease current status and transplantation consideration].2023Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatologyFree full text
  4. [Value of radiomics model based on dynamic contrast-enhanced magnetic resonance imaging in differentiation fat-poor angiomyolipoma from alpha-fetoprotein-negative hepatocellular carcinoma in the background of non-cirrhotic liver].2022Zhonghua yi xue za zhi
All its trials on ClinicalTrials.gov, any status14
  1. Lenvatinib, Tislelizumab Combined With RALOX Regimen HAIC in Advanced Hepatocellular CarcinomaRecruitingNCT05954897Lead sponsorPhase 2Start 2023-09
  2. Head-to-head Comparison of Positron Nuclide Radio-labeled FAPI and 18F-FDG PET/CT in Patients With Malignant TumorsStatus unknownNCT06182644Lead sponsorN/AStart 2024-01
  3. Decrease in Circulating Tumour Cell Count Reflects the Effectiveness of Postoperative Adjuvant Transarterial Chemoembolization (TACE) in Preventing Hepatocellular Carcinoma RecurrenceCompletedNCT02032368Lead sponsorN/AStart 2010-07
  4. Different Protocols for Repeated Transarterial Chemoembolization in the Treatment of Patients With Hepatocellular CarcinomaCompletedNCT02038296Lead sponsorPhase 3Start 2008-01
  5. A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)Active, not recruitingNCT04344158Study sitePhase 3Start 2020-08
  6. Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937)CompletedNCT03867084Study sitePhase 3Start 2019-05
  7. Lenvatinib Plus Nivolumab Versus Lenvatinib for Advanced Hepatocellular Carcinoma With Hepatitis B Virus InfectionWithdrawnNCT04044651Study sitePhase 2/Phase 3Start 2019-10
  8. Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Lenvatinib as First-line Therapy in Participants With Advanced Hepatocellular Carcinoma (MK-7902-002/E7080-G000-311/LEAP-002)CompletedNCT03713593Study sitePhase 3Start 2018-12
  9. Study of Pembrolizumab (MK-3475) or Placebo Given With Best Supportive Care in Asian Participants With Previously Treated Advanced Hepatocellular Carcinoma (MK-3475-394/KEYNOTE-394)CompletedNCT03062358Study sitePhase 3Start 2017-04
  10. A Study of Tislelizumab Versus Sorafenib in Participants With Unresectable Hepatocellular Carcinoma (HCC)CompletedNCT03412773Study sitePhase 3Start 2017-12
  11. A Study to Evaluate SHR-1210 in Subjects With Advanced HCCCompletedNCT02989922Study sitePhase 2Start 2016-11
  12. Study of ThermoDox With Standardized Radiofrequency Ablation (RFA) for Treatment of Hepatocellular Carcinoma (HCC)CompletedNCT02112656Study sitePhase 3Start 2014-06
  13. Axitinib For The Treatment Of Advanced Hepatocellular CarcinomaCompletedNCT01210495Study sitePhase 2Start 2010-12
  14. Urea Cream Treatment Sorafenib-Associated HSFR in HCCCompletedNCT01934829Study sitePhase 2Start 2009-07

Run the PubMed searchClinicalTrials.gov

Cancer

Stomach cancer

胃癌

Led 21 of the 9,782 English-language PubMed papers on stomach cancer with an author in mainland China, 2021–2025: 0.2%.

Papers led
21
2021–2025
Trials led
4
any status, ClinicalTrials.gov
Open trials led
1
recruiting or about to
Open trials as a site
7
led by another institution
Papers led per year
2021: 0020212022: 2220222023: 4420232024: 6620242025: 992025

15 hospitals in Guangzhou for stomach cancer211 hospitals in China for stomach cancer

Open trials with this hospital 8

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Not yet recruiting
    Evaluation of Pressurized Intraperitoneal Aerosol Chemotherapy With VRT106 Versus PIPAC in Patients With Advanced Gastric Cancer and PeritonealMetastasis: A Prospective, Multicenter, Open-Label, Randomized Controlled Trial
    Phase
    Phase 2
    Started
    2026-03
    Registry
    NCT07486310

    Age 18 years to 75 years (registered criteria)

    Led by Guangdong Provincial People's HospitalGuangzhou

  2. Recruiting
    Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.
    Phase
    Phase 3
    Started
    2026-04
    Registry
    NCT07385703

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 64 listed hospitals as study sitesAnyang, Beijing, Changchun, Changsha, Changzhou, Chengde, Chengdu, Chongqing, Fuzhou, Guangzhou, Haikou, Hangzhou, Hefei, Jinan, Kunming, Lanzhou, Linyi, Luoyang, Nanchang, Nanchong, Nanjing, Qingdao, Shanghai, Shantou, Shenyang, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Urumqi, Wuhan, Xi'an, Xiamen, Xuzhou, Yangzhou, Zhengzhou

  3. Recruiting
    Phase 3 Study of Cadonilimab Combined With Chemotherapy vs Chemotherapy in Combination With or Without Nivolumab for the 1L Treatment of Participants With HER2-negative, Previously Untreated, Unresectable or Metastatic Gastric/GEJ Adenocarcinoma
    Phase
    Phase 3
    Started
    2026-09
    Registry
    NCT07700979

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesBeijing, Guangzhou, Shanghai

  4. Recruiting
    Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in China
    Phase
    Not given
    Started
    2025-02
    Registry
    NCT06846996

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 32 listed hospitals as study sitesBeijing, Changchun, Fuzhou, Guangzhou, Haikou, Hangzhou, Nanjing, Shanghai, Shantou, Shenyang, Taiyuan, Taizhou, Tianjin, Xuzhou, Zhengzhou

  5. Recruiting
    Prediction of Peritoneal Metastasis for Gastric Cancer Based on Radiomics
    Phase
    Not given
    Started
    2023-01
    Registry
    NCT05722275

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 10 listed hospitals as study sitesBeijing, Fuzhou, Guangzhou, Kunming, Taiyuan, Zhengzhou

  6. Recruiting
    Perioperative Disitamab Vedotin Plus Toripalimab and XELOX in Gastric or Gastroesophageal Junction Adenocarcinoma.
    Phase
    Phase 2
    Started
    2023-11
    Registry
    NCT06155383

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 10 listed hospitals as study sitesBeijing, Chengdu, Fuzhou, Guangzhou, Harbin, Jinan, Kunming, Xiamen, Zhengzhou

  7. Recruiting
    Docetaxel, Oxaliplatin and 5-FU for Gastric Cancer With Inoperable Malignant Bowel Obstruction
    Phase
    Phase 2
    Started
    2022-01
    Registry
    NCT04840264

    Age 18 years to 75 years (registered criteria)

    Led by Sixth Affiliated Hospital of Sun Yat-sen University; 1 listed hospital as study siteGuangzhou

  8. Recruiting
    OGT-assisted Overlap Esophagojejunostomy Versus Traditional Overlap Method
    Phase
    N/A
    Started
    2022-09
    Registry
    NCT05450835

    Age 18 years to 75 years (registered criteria)

    Led by Nanfang Hospital; 7 listed hospitals as study sitesChangchun, Changsha, Guangzhou, Shantou, Shenyang

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesNutrition & recoverySurgeryImaging & AI
Departments in papersPathology / laboratory medicineGastroenterology / hepatologyRadiology / nuclear medicine
Papers it led21
  1. Multitask Deep Learning Based on Longitudinal CT Images Facilitates Prediction of Lymph Node Metastasis and Survival in Chemotherapy-Treated Gastric Cancer.2025Cancer research
  2. EGR4 transcriptionally upregulates GDF15 to promote gastric cancer metastasis.2025Cell death & diseaseFree full text
  3. CXCL12 expression and the survival of patients with gastric cancer: a meta-analysis.2025Clinical and experimental medicineFree full text
  4. Integrative analysis of bulk and single-cell sequencing reveals TNFSF9 as a potential regulator in microsatellite instability stomach adenocarcinoma.2025European journal of medical researchFree full text
  5. Role of m7G modification regulators as biomarkers in gastric cancer subtyping and precision immunotherapy.2025International immunopharmacology
  6. LGALS9B stabilizes EEF1D protein and activates the PI3K/AKT signaling pathway to promote gastric cancer occurrence and metastasis.2025Oncogene
  7. Diagnostic challenges of rarely well-differentiated adenocarcinoma of the stomach.2025Pathology oncology research : PORFree full text
  8. Single-cell RNA sequencing analysis revealed the immunosuppressive remodeling of tumor-associated macrophages mediated by the MIF-CD74 axis in gastric cancer.2025Scientific reportsFree full text
  9. Hepatic Portal Venous Gas and Pneumatosis Intestinalis Associated With Early Oral Feeding After Laparoscopic Total Gastrectomy.2025The American surgeon
  10. KDM3A Ablation Activates Endogenous Retrovirus Expression to Stimulate Antitumor Immunity in Gastric Cancer.2024Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  11. Identification of chronic non-atrophic gastritis and intestinal metaplasia stages in the Correa's cascade through machine learning analyses of SERS spectral signature of non-invasively-collected human gastric fluid samples.2024Biosensors & bioelectronics
  12. Comparative single-cell analysis reveals heterogeneous immune landscapes in adenocarcinoma of the esophagogastric junction and gastric adenocarcinoma.2024Cell death & diseaseFree full text
  13. GLT8D2 is a prognostic biomarker and regulator of immune cell infiltration in gastric cancer.2024Frontiers in immunologyFree full text
  14. The prognostic implications and tumor-promoting functions of CHSY3 in gastric cancer.2024Frontiers in immunologyFree full text
  15. m6A modification enhances the stability of CDC25A promotes tumorigenicity of esophagogastric junction adenocarcinoma via cell cycle.2024International journal of biological sciencesFree full text
  16. Prognostic value of a new staging system for adenocarcinoma of the esophagogastric junction after preoperative radiation therapy.2023Asian journal of surgery
  17. Lymph node evaluation after neoadjuvant therapy for patients with adenocarcinoma of the esophagogastric junction.2023Asian journal of surgery
  18. Clinical characteristics and prognostic outcomes for adenocarcinoma of esophagogastric junction in early-onset patients: a population-based appraisal.2023Journal of cancer research and clinical oncologyFree full text
  19. Profiling of the genetic features of Chinese patients with gastric cancer with HRD germline mutations in a large-scale retrospective study.2023Journal of medical geneticsFree full text
  20. Evaluation of proton pump inhibitors and risks of gastric cancer.2022Gut
  21. The ratio of serum C-reactive protein level on postoperative day 3 to day 2 is a good marker to predict postoperative complications after laparoscopic radical gastrectomy for gastric cancer.2022Langenbeck's archives of surgeryRCTFree full text
Chinese-language papers (not in the count)3
  1. [High expression of CREM is associated with poor prognosis in gastric cancer patients].2024Nan fang yi ke da xue xue bao = Journal of Southern Medical UniversityFree full text
  2. [Application of laparoscopic and open gastrectomy in enhanced recovery after surgery for gastric cancer: analysis of data from multiple centers in China].2021Nan fang yi ke da xue xue bao = Journal of Southern Medical UniversityFree full text
  3. [Expression of nicotinamide-N-methyltransferase in gastric cancer and its biological and clinicopathological significance].2021Nan fang yi ke da xue xue bao = Journal of Southern Medical UniversityFree full text
All its trials on ClinicalTrials.gov, any status31
  1. Evaluation of Pressurized Intraperitoneal Aerosol Chemotherapy With VRT106 Versus PIPAC in Patients With Advanced Gastric Cancer and PeritonealMetastasis: A Prospective, Multicenter, Open-Label, Randomized Controlled TrialNot yet recruitingNCT07486310Lead sponsorPhase 2Start 2026-03
  2. A Randomized Controlled Study of Serplulimab Combined With Chemotherapy for Locally Advanced Gastric AdenocarcinomaActive, not recruitingNCT07257575Lead sponsorPhase 2Start 2025-01
  3. Head-to-head Comparison of Positron Nuclide Radio-labeled FAPI and 18F-FDG PET/CT in Patients With Malignant TumorsStatus unknownNCT06182644Lead sponsorN/AStart 2024-01
  4. Clinical Study on Treatment of Apatinib Mesylate in First-line Maintenance of Advanced Gastric CancerStatus unknownNCT03255811Lead (inferred)N/AStart 2017-03
  5. Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.RecruitingNCT07385703Study sitePhase 3Start 2026-04
  6. Phase 3 Study of Cadonilimab Combined With Chemotherapy vs Chemotherapy in Combination With or Without Nivolumab for the 1L Treatment of Participants With HER2-negative, Previously Untreated, Unresectable or Metastatic Gastric/GEJ AdenocarcinomaRecruitingNCT07700979Study sitePhase 3Start 2026-09
  7. Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in ChinaRecruitingNCT06846996Study siteStart 2025-02
  8. Perioperative Disitamab Vedotin Plus Toripalimab and XELOX in Gastric or Gastroesophageal Junction Adenocarcinoma.RecruitingNCT06155383Study sitePhase 2Start 2023-11
  9. Prediction of Peritoneal Metastasis for Gastric Cancer Based on RadiomicsRecruitingNCT05722275Study siteStart 2023-01
  10. OGT-assisted Overlap Esophagojejunostomy Versus Traditional Overlap MethodRecruitingNCT05450835Study siteN/AStart 2022-09
  11. Docetaxel, Oxaliplatin and 5-FU for Gastric Cancer With Inoperable Malignant Bowel ObstructionRecruitingNCT04840264Study sitePhase 2Start 2022-01
  12. A Study of SGN-B6A in Chinese Participants With Advanced Solid TumorsCompletedNCT06549816Study sitePhase 1Start 2024-08
  13. Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) OverexpressionCompletedNCT05052801Study sitePhase 3Start 2022-03
  14. Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer.TerminatedNCT05111626Study sitePhase 3Start 2022-03
  15. A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-OverexpressionStatus unknownNCT04714190Study sitePhase 3Start 2021-03
  16. A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal CancersActive, not recruitingNCT05152147Study sitePhase 3Start 2021-12
  17. Anti-HER2 Bispecific Antibody Zanidatamab (ZW25) Activity in Combination With Chemotherapy With/Without TislelizumabCompletedNCT04276493Study sitePhase 1/Phase 2Start 2020-03
  18. Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy, Phase 1 Study of CMG901CompletedNCT04805307Study sitePhase 1Start 2020-12
  19. Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)Active, not recruitingNCT04152499Study sitePhase 1/Phase 2Start 2020-02
  20. Acupuncture for QoL and Symptoms in Gastric Cancer During Adjuvant ChemotherapyCompletedNCT04360577Study siteN/AStart 2020-05
  21. A Study to Confirm the Accuracy of Locally Advanced Gastric Cancer DiagnosisStatus unknownNCT04440605Study siteStart 2020-07
  22. Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)CompletedNCT03675737Study sitePhase 3Start 2018-11
  23. Laparoscopic D2 Distal Gastrectomy Following Neoadjuvant Chemotherapy for Locally Advanced Gastric CancersStatus unknownNCT03468712Study siteN/AStart 2018-03
  24. Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)CompletedNCT03615326Study sitePhase 3Start 2018-10
  25. Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)-China ExtensionWithdrawnNCT04859582Study sitePhase 3Start 2018-11
  26. Incidence of Pancreatic Fistula After Radical GastrectomyStatus unknownNCT03391687Study siteStart 2017-12
  27. A Study of Paclitaxel With or Without Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal CancerCompletedNCT02898077Study sitePhase 3Start 2017-03
  28. Study on Laparoscopic Spleen-Preserving No. 10 Lymph Node Dissection for Advanced Gastric CancerStatus unknownNCT02845986Study sitePhase 2Start 2016-09
  29. Cytoreductive Surgery Combined With HIPEC and Chemotherapy for Gastric Cancer With Peritoneal MetastasisStatus unknownNCT03023436Study sitePhase 3Start 2016-01
  30. Efficacy of HIPEC in the Treatment of Locally Advanced Gastric Cancer After radIcal Gastrectomy With D2Status unknownNCT02356276Study sitePhase 3Start 2015-05
  31. Ultrasonic Scalpel vs. Monopolar Electrocautery for D2 Distal Gastric Carcinoma SurgeryStatus unknownNCT02130752Study siteN/AStart 2014-10

Run the PubMed searchClinicalTrials.gov

Cancer

Hepatoblastoma

肝母细胞瘤

Led 1 of the 154 English-language PubMed papers on hepatoblastoma with an author in mainland China, 2021–2025: 0.7%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

8 hospitals in Guangzhou for hepatoblastoma86 hospitals in China for hepatoblastoma

No open trial on hepatoblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersSurgery (general/hepatobiliary/pancreatic)

Run the PubMed searchClinicalTrials.gov

Cancer

Retinoblastoma

视网膜母细胞瘤

Led 2 of the 301 English-language PubMed papers on retinoblastoma with an author in mainland China, 2021–2025: 0.7%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 1120242025: 002025

8 hospitals in Guangzhou for retinoblastoma176 hospitals in China for retinoblastoma

No open trial on retinoblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersOphthalmology / neuro-ophthalmologyRadiology / nuclear medicine

Run the PubMed searchClinicalTrials.gov

Cancer

Chordoma

脊索瘤

Led 1 of the 105 English-language PubMed papers on chordoma with an author in mainland China, 2021–2025: 0.9%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

4 hospitals in Guangzhou for chordoma84 hospitals in China for chordoma

No open trial on chordoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Cancer

Osteosarcoma

骨肉瘤

Led 11 of the 2,257 English-language PubMed papers on osteosarcoma with an author in mainland China, 2021–2025: 0.5%.

Papers led
11
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 2220212022: 0020222023: 3320232024: 2220242025: 442025

30 hospitals in Guangzhou for osteosarcoma570 hospitals in China for osteosarcoma

No open trial on osteosarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Over half of these papers are lab or animal studies.

Papers it led11
  1. Implant derived high local concentration of magnesium inhibits tumorigenicity of osteosarcoma.2025Biomaterials
  2. Microwave-triggered organic sensitizer for synergistic dynamic/thermal therapy of osteosarcoma.2025Biomaterials science
  3. AZIN1-dependent polyamine synthesis accelerates tumor cell cycle progression and impairs effector T-cell function in osteosarcoma.2025Cell death & disease
  4. Personalized prediction of chemotherapy efficacy in osteosarcoma through patient-derived organoids: correlation with survival and tumor proliferation potential.2025Journal of experimental & clinical cancer research : CR
  5. Dual Factor-Loaded Artificial Periosteum Accelerates Bone Regeneration.2024ACS biomaterials science & engineering
  6. Establishment of orthotopic osteosarcoma animal models in immunocompetent rats through muti-rounds of in-vivo selection.2024BMC cancer
  7. Molecular Mechanism Underlying the Action of a Celastrol-Loaded Layered Double Hydroxide-Coated Magnesium Alloy in Osteosarcoma Inhibition and Bone Regeneration.2023ACS biomaterials science & engineering
  8. Multifunctional 3D-printed scaffolds eradiate orthotopic osteosarcoma and promote osteogenesis via microwave thermo-chemotherapy combined with immunotherapy.2023Biomaterials
  9. Biodegradable photothermal thermosensitive hydrogels treat osteosarcoma by reprogramming macrophages.2023Biomaterials science
  10. Nitrogen-containing bisphosphonate-loaded micro-arc oxidation coating for biodegradable magnesium alloy pellets inhibits osteosarcoma through targeting of the mevalonate pathway.2021Acta biomaterialia
  11. Pharmacological Inhibition of Core Regulatory Circuitry Liquid-liquid Phase Separation Suppresses Metastasis and Chemoresistance in Osteosarcoma.2021Advanced science (Weinheim, Baden-Wurttemberg, Germany)
Earlier papers (2016–2020)1
  1. LncRNA FTX inhibition restrains osteosarcoma proliferation and migration via modulating miR-320a/TXNRD1.2020Cancer biology & therapy
All its trials on ClinicalTrials.gov, any status1
  1. IM83 Clinical Study of CAR-T Cell Therapy in Patients With Relapsed or Refractory OsteosarcomaStatus unknownNCT06412458Study sitePhase 1Start 2024-06

Run the PubMed searchClinicalTrials.gov

Cancer

Gastrointestinal stromal tumour

胃肠道间质瘤

Led 1 of the 523 English-language PubMed papers on gastrointestinal stromal tumour with an author in mainland China, 2021–2025: 0.2%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

12 hospitals in Guangzhou for gastrointestinal stromal tumour240 hospitals in China for gastrointestinal stromal tumour

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Study of HQP1351 in Patients With GIST or Other Solid Tumors
    Phase
    Phase 1
    Started
    2018-07
    Registry
    NCT03594422

    Age 12 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesBeijing, Guangzhou, Shanghai, Wuhan, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersMedical oncology

Run the PubMed searchClinicalTrials.gov

Cancer

Neuroblastoma

神经母细胞瘤

Led no English-language PubMed papers on neuroblastoma in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

22 hospitals in Guangzhou for neuroblastoma321 hospitals in China for neuroblastoma

No open trial on neuroblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Earlier papers (2016–2020)2
  1. [Effect of hot water extract of Korean ginseng on neuroblastoma cell parthanatos].2020Nan fang yi ke da xue xue bao = Journal of Southern Medical University
  2. Adrenal neuroblastoma in an elderly adult: a case report and review of the literature.2019Journal of medical case reports

Run the PubMed searchClinicalTrials.gov

Blood disorders

Multiple myeloma

多发性骨髓瘤

Led 3 of the 1,676 English-language PubMed papers on multiple myeloma with an author in mainland China, 2021–2025: 0.2%.

Papers led
3
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
3
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 1120242025: 112025

14 hospitals in Guangzhou for multiple myeloma175 hospitals in China for multiple myeloma

Open trials with this hospital 3

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
    Phase
    Phase 1
    Started
    2026-05
    Registry
    NCT07477587

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 46 listed hospitals as study sitesBeijing, Bengbu, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Nanchang, Nanjing, Ningbo, Qingdao, Shanghai, Shenyang, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Weifang, Wenzhou, Wuhan, Wuxi, Xiamen, Xuzhou, Zhengzhou

  2. Recruiting
    A Clinical Study Assessing the Subcutaneous Formulation of TQB2934 for Injection in Subjects With Malignant Plasma Cell Tumors
    Phase
    Phase 1
    Started
    2025-12
    Registry
    NCT07179679

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 11 listed hospitals as study sitesChengde, Chongqing, Guangzhou, Nanchang, Nanchong, Nanjing, Shanghai, Suzhou, Xi'an

  3. Recruiting
    A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
    Phase
    Phase 3
    Started
    2021-10
    Registry
    NCT05020236

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 20 listed hospitals as study sitesBeijing, Changchun, Chongqing, Fuzhou, Guangzhou, Hangzhou, Jinan, Nanchang, Nanjing, Shenzhen, Shijiazhuang, Tianjin, Wenzhou, Wuhan, Xuzhou, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesBispecific & antibody drugsDiagnosis, MRD & riskKidney & bone complications
Papers it led3
  1. The effects of daratumumab on bone disease in patients with newly diagnosed multiple myeloma: a multi-center retrospective study.2025BMC cancerFree full text
  2. Induction Chemotherapy-Related Covert Cardiac Remodeling in Pre-Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma: A Retrospective Observational Study.2024Cancer medicineFree full text
  3. C3aR costimulation enhances the antitumor efficacy of CAR-T cell therapy through Th17 expansion and memory T cell induction.2022Journal of hematology & oncologyFree full text
All its trials on ClinicalTrials.gov, any status20
  1. A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple MyelomaRecruitingNCT07477587Study sitePhase 1Start 2026-05
  2. A Clinical Study Assessing the Subcutaneous Formulation of TQB2934 for Injection in Subjects With Malignant Plasma Cell TumorsRecruitingNCT07179679Study sitePhase 1Start 2025-12
  3. A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other TreatmentsRecruitingNCT05020236Study sitePhase 3Start 2021-10
  4. A Study to Learn About the Study Medicine (Maplirpacept) in People With Advanced Non-Hodgkin Lymphoma or Multiple Myeloma in ChinaCompletedNCT05896774Study sitePhase 1Start 2023-06
  5. Study of 3D189 in Patients With Hematologic MalignanciesCompletedNCT05320809Study sitePhase 1Start 2022-08
  6. Selinexor Plus VRd in High Risk Newly Diagnosed Multiple MyelomaStatus unknownNCT05422027Study sitePhase 1/Phase 2Start 2022-07
  7. A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to TreatmentActive, not recruitingNCT05455320Study sitePhase 3Start 2022-10
  8. A Study of DaratumumabActive, not recruitingNCT05438043Study sitePhase 3Start 2022-12
  9. A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma.CompletedNCT05228470Study sitePhase 2Start 2021-12
  10. A Study of Evaluating the Safety and Efficacy of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)CompletedNCT04939142Study sitePhase 3Start 2021-07
  11. A Ph1/2 Study of EMB-06 in Participants With Relapsed or Refractory MyelomaTerminatedNCT04735575Study sitePhase 1/Phase 2Start 2021-05
  12. Clinical Trial to Evaluate CT053 in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 1)Status unknownNCT03975907Study sitePhase 1/Phase 2Start 2019-06
  13. A Study of Evaluating the Safety and Efficacy of ATG-010 in Relapsed Refractory Multiple MyelomaCompletedNCT03944057Study sitePhase 2Start 2019-09
  14. TJ202, Lenalidomide and Dexamethasone vs. Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple MyelomaCompletedNCT03952091Study sitePhase 3Start 2019-03
  15. A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.Active, not recruitingNCT03539744Study sitePhase 3Start 2018-10
  16. A Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-Dose Therapy (Asia Pacific Region)CompletedNCT03217812Study sitePhase 3Start 2017-11
  17. A Study to Compare Daratumumab, Bortezomib, and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in Chinese Participants With Relapsed or Refractory Multiple MyelomaCompletedNCT03234972Study sitePhase 3Start 2017-11
  18. Phase 3 Study of Carfilzomib, Melphalan, Prednisone vs Bortezomib, Melphalan, Prednisone in Newly Diagnosed Multiple MyelomaCompletedNCT01818752Study sitePhase 3Start 2013-07
  19. Open-label Extended Access Program on Lenalidomide Plus Dexamethasone in Chinese Subjects With Relapsed/Refractory Multiple Myeloma Who Participated in CC-5013-MM021 for at Least 1 YearCompletedNCT02348528Study sitePhase 2Start 2012-09
  20. Study of Lenalidomide and Low-Dose Dexamethasone in Chinese Subjects With Relapsed/Refractory Multiple MyelomaCompletedNCT01593410Study sitePhase 2Start 2010-08

Run the PubMed searchClinicalTrials.gov

Blood disorders

B-cell acute lymphoblastic leukaemia

B 细胞急性淋巴细胞白血病

Led 1 of the 225 English-language PubMed papers on B-cell acute lymphoblastic leukaemia with an author in mainland China, 2021–2025: 0.4%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

8 hospitals in Guangzhou for B-cell acute lymphoblastic leukaemia88 hospitals in China for B-cell acute lymphoblastic leukaemia

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Study of YK012 in B-cell Acute Lymphoblastic Leukemia
    Phase
    Phase 1/Phase 2
    Started
    2024-09
    Registry
    NCT06580301

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 8 listed hospitals as study sitesChangchun, Guangzhou, Guiyang, Hangzhou, Nanchang, Xuzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesPhiladelphia chromosome & geneticsChildren
Departments in papersPediatrics
Papers it led1
  1. HOX11 gene overexpression is associated with recurrence of acute B lymphoblastic leukaemia.2025British journal of haematology
All its trials on ClinicalTrials.gov, any status3
  1. Study of YK012 in B-cell Acute Lymphoblastic LeukemiaRecruitingNCT06580301Study sitePhase 1/Phase 2Start 2024-09
  2. A Study of Ponsegromab in People With Heart FailureTerminatedNCT05492500Study sitePhase 2Start 2022-09
  3. Efficacy and Safety of the BiTE Antibody Blinatumomab in Chinese Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL)CompletedNCT03476239Study sitePhase 3Start 2017-10

Run the PubMed searchClinicalTrials.gov

Blood disorders

Beta thalassaemia

β 地中海贫血

Led 1 of the 312 English-language PubMed papers on beta thalassaemia with an author in mainland China, 2021–2025: 0.3%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

18 hospitals in Guangzhou for beta thalassaemia133 hospitals in China for beta thalassaemia

No open trial on beta thalassaemia lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersPathology / laboratory medicine

Run the PubMed searchClinicalTrials.gov

Other diseases

Neuromyelitis optica spectrum disorder

视神经脊髓炎谱系疾病

Led 3 of the 485 English-language PubMed papers on neuromyelitis optica spectrum disorder with an author in mainland China, 2021–2025: 0.6%.

Papers led
3
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 2220242025: 002025

9 hospitals in Guangzhou for neuromyelitis optica spectrum disorder67 hospitals in China for neuromyelitis optica spectrum disorder

No open trial on neuromyelitis optica spectrum disorder lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesAntibodies & diagnosisImagingOptic nerve & vision
Departments in papersNeurologyOphthalmology / neuro-ophthalmology

Run the PubMed searchClinicalTrials.gov

Other diseases

IgG4-related disease

IgG4相关性疾病

Led 3 of the 246 English-language PubMed papers on IgG4-related disease with an author in mainland China, 2021–2025: 1.2%.

Papers led
3
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 222025

2 hospitals in Guangzhou for IgG4-related disease46 hospitals in China for IgG4-related disease

No open trial on IgG4-related disease lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesDiagnosis & look-alikesKidney, retroperitoneum & vessels
Departments in papersPathology / laboratory medicineNephrologyRadiology / nuclear medicine
Papers it led3
  1. Comparison of clinical features between patients with and without renal involvement in IgG4-related disease.2025Clinical and experimental medicineFree full text
  2. Clinical and laboratory characteristics of IgG4-related disease involving multiple organs.2025Clinical rheumatology
  3. IgG4-related disease involving the cervical spinal cord.2024Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
More papers found outside PubMed (not counted)1
  1. The assessment of 18F-FDG PET/CT in IgG4-related disease: Case report and review of the literature2024Indian Journal of Ophthalmology - Case Reportsarticle

Run the PubMed searchClinicalTrials.gov

Other diseases

Myasthenia gravis

重症肌无力

Led 1 of the 499 English-language PubMed papers on myasthenia gravis with an author in mainland China, 2021–2025: 0.2%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

7 hospitals in Guangzhou for myasthenia gravis89 hospitals in China for myasthenia gravis

No open trial on myasthenia gravis lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesThymus & thymectomyPregnancy, children, older adults
Departments in papersNeurology

Run the PubMed searchClinicalTrials.gov

Other diseases

Takayasu arteritis

大动脉炎

Led no English-language PubMed papers on Takayasu arteritis in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

6 hospitals in Guangzhou for Takayasu arteritis100 hospitals in China for Takayasu arteritis

No open trial on Takayasu arteritis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
All its trials on ClinicalTrials.gov, any status1
  1. A Study to Evaluate the Efficacy and Safety of Upadacitinib in Participants With Takayasu Arteritis (TAK)Active, not recruitingNCT04161898Study sitePhase 3Start 2020-02

Run the PubMed searchClinicalTrials.gov

Other diseases

Idiopathic pulmonary fibrosis

特发性肺纤维化

Led 2 of the 989 English-language PubMed papers on idiopathic pulmonary fibrosis with an author in mainland China, 2021–2025: 0.2%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 1120232024: 0020242025: 002025

20 hospitals in Guangzhou for idiopathic pulmonary fibrosis288 hospitals in China for idiopathic pulmonary fibrosis

No open trial on idiopathic pulmonary fibrosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Amyotrophic lateral sclerosis

肌萎缩侧索硬化症

Led 1 of the 779 English-language PubMed papers on amyotrophic lateral sclerosis with an author in mainland China, 2021–2025: 0.1%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

13 hospitals in Guangzhou for amyotrophic lateral sclerosis182 hospitals in China for amyotrophic lateral sclerosis

No open trial on amyotrophic lateral sclerosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNeurology

Run the PubMed searchClinicalTrials.gov

Other diseases

Fabry disease

法布雷病

Led 1 of the 73 English-language PubMed papers on Fabry disease with an author in mainland China, 2021–2025: 1.4%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

3 hospitals in Guangzhou for Fabry disease80 hospitals in China for Fabry disease

No open trial on Fabry disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Behçet disease

白塞病

Led 1 of the 245 English-language PubMed papers on Behçet disease with an author in mainland China, 2021–2025: 0.4%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

7 hospitals in Guangzhou for Behçet disease139 hospitals in China for Behçet disease

No open trial on Behçet disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

IgA nephropathy

IgA 肾病

Led 8 of the 736 English-language PubMed papers on IgA nephropathy with an author in mainland China, 2021–2025: 1.1%.

Papers led
8
2021–2025
Trials led
7
any status, ClinicalTrials.gov
Open trials led
1
recruiting or about to
Open trials as a site
2
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 3320232024: 2220242025: 222025

16 hospitals in Guangzhou for IgA nephropathy300 hospitals in China for IgA nephropathy

Open trials with this hospital 3

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Correlation of Microbiome and Metabonomics With IgA Nephropathy
    Phase
    Not given
    Started
    2020-05
    Registry
    NCT05190848

    Age 16 years to 65 years (registered criteria)

    Led by Guangdong Provincial People's Hospital; 4 listed hospitals as study sitesGuangzhou

  2. Recruiting
    A Study of SC0062 Capsule for the Treatment of IgA Nephropathy with Proteinuria
    Phase
    Phase 3
    Started
    2025-02
    Registry
    NCT06819826

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou

  3. Recruiting
    A Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy
    Phase
    Phase 3
    Started
    2025-07
    Registry
    NCT06963827

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 20 listed hospitals as study sitesBaotou, Beijing, Changsha, Chengdu, Guangzhou, Hangzhou, Jinan, Nanchang, Nanjing, Nantong, Ningbo, Shanghai, Shenzhen, Wuxi, Xiamen, Zhuhai

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersNephrology
Papers it led8
  1. Effectiveness and safety of finerenone in the treatment of IgA Nephrology patients: a retrospective, real-world study.2025International urology and nephrology
  2. Lysosome-mediated aggregation of galactose-deficient IgA1 with transferrin receptor 1 links to IgA nephropathy.2025Nature communications
  3. Identification of susceptibility loci and relevant cell type for IgA nephropathy in Han Chinese by integrative genome-wide analysis.2024Frontiers of medicine
  4. The risk factor for adverse pregnancy outcomes and its impact on clinical effect in IgA nephropathy: A retrospective observational study.2024Nephrology (Carlton, Vic.)
  5. Genome-Wide Association Analysis of Protein-Coding Variants in IgA Nephropathy.2023Journal of the American Society of Nephrology : JASN
  6. Anomalous kinetics of galactose-deficient IgA incurring nephropathy revealed by cross-scale optical imaging.2023Kidney international
  7. Systematic Microbiome Dysbiosis Is Associated with IgA Nephropathy.2023Microbiology spectrum
  8. Increased proportion of follicular helper T cells is associated with B cell activation and disease severity in IgA nephropathy.2022Frontiers in immunology
Chinese-language papers (not in the count)2
  1. [High serum cystatin C is an independent risk factor for poor renal prognosis in IgA nephropathy].2025Nan fang yi ke da xue xue bao = Journal of Southern Medical University
  2. [Current status and prospects of genetic research on IgA nephropathy].2024Zhonghua yi xue za zhi
Earlier papers (2016–2020)1
  1. M2a and M2b macrophages predominate in kidney tissues and M2 subpopulations were associated with the severity of disease of IgAN patients.2019Clinical immunology (Orlando, Fla.)
All its trials on ClinicalTrials.gov, any status14
  1. Correlation of Microbiome and Metabonomics With IgA NephropathyRecruitingNCT05190848Lead sponsorStart 2020-05
  2. Universal STAR-T Cell Injection in Autoimmune Kidney DiseasesNot yet recruitingNCT07746453Lead sponsorN/AStart 2026-08
  3. Extended Follow-up of Treatment of Prednisone Plus Cyclophosphamide in Patients With Advanced-stage IgA NephropathyStatus unknownNCT03218852Lead sponsorPhase 4Start 2016-12
  4. A Survey of Factors Affecting an Early or Delayed Diagnosis of IgA NephropathyCompletedNCT01538433Lead sponsorStart 2012-02
  5. Treatment of Prednisone Plus Cyclophosphamide in Patients With Advanced-stage IgA NephropathyStatus unknownNCT01758120Lead sponsorPhase 4Start 2012-12
  6. An Observational Study of IgA Nephropathy: Pathological Variants and Clinical DataCompletedNCT01502579Lead sponsorStart 2011-09
  7. A Study of the Antioxidant Probucol Combined With Valsartan in Patients With IgA NephropathyCompletedNCT00426348Lead sponsorPhase 4Start 2007-05
  8. A Study of Mezagitamab in Adults With Kidney Condition Called IgA NephropathyRecruitingNCT06963827Study sitePhase 3Start 2025-07
  9. A Study of SC0062 Capsule for the Treatment of IgA Nephropathy with ProteinuriaRecruitingNCT06819826Study sitePhase 3Start 2025-02
  10. A Clinical Study of SCTC21C in Participants With Plasma Cell-driven Autoimmune DiseasesNot yet recruitingNCT06774664Study sitePhase 1/Phase 2Start 2025-01
  11. A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of ProgressionActive, not recruitingNCT05797610Study sitePhase 3Start 2023-08
  12. A Study of Telitacicept for IgA Nephropathy (TELIGAN)Active, not recruitingNCT05799287Study sitePhase 3Start 2023-04
  13. TESTING -ON Post-Trial ObservatioNal Cohort StudyCompletedNCT05434325Study siteStart 2022-12
  14. Therapeutic Evaluation of Steroids in IgA Nephropathy Global Study (TESTING Low Dose Study)CompletedNCT01560052Study siteN/AStart 2012-05

Run the PubMed searchClinicalTrials.gov

Other diseases

Primary biliary cholangitis

原发性胆汁性胆管炎

Led 4 of the 300 English-language PubMed papers on primary biliary cholangitis with an author in mainland China, 2021–2025: 1.3%.

Papers led
4
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 1120232024: 1120242025: 112025

9 hospitals in Guangzhou for primary biliary cholangitis153 hospitals in China for primary biliary cholangitis

No open trial on primary biliary cholangitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Primary sclerosing cholangitis

原发性硬化性胆管炎

Led 1 of the 100 English-language PubMed papers on primary sclerosing cholangitis with an author in mainland China, 2021–2025: 1.0%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

8 hospitals in Guangzhou for primary sclerosing cholangitis89 hospitals in China for primary sclerosing cholangitis

No open trial on primary sclerosing cholangitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other linked evidence

Getting in touch

Name card to show staff or a driver

广东省人民医院

Guangdong Provincial People's Hospital

广州

Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.

Inquiry letter in English and Chinese

Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.

Records hospitals usually ask for

  • A recent summary or letter from the treating doctor
  • Pathology report
  • Scans (CT, MRI, PET) with their reports, and the images if possible
  • Treatments so far, with dates
  • Current medicines

What to do next

Talk with the treating doctorThis page can be shared with the treating doctor to discuss whether this team's work is relevant.
Check the team is still therePapers lag by months and doctors move. Look for the department on the hospital's own website.
Contact the hospital directlyUse the hospital's own contacts. Hospitals never pay us, and each hospital decides which patients it accepts.

Where these numbers come from

Papers

English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions

Trials

ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.

Identifiers and other names

ROR
Guangdong General Hospital; Guangdong Academy of Medical Sciences; Guangdong Provincial People's Hospital Heyuan Hospital; Guangdong General Hospital/Guangdong Academy of Medical Sciences; Guangdong General Hospital & Guangdong Academy of Medical Sciences; Guangdong Academy of Medical Sciences/Guangdong General Hospital; Ganzhou Hospital of Guangdong Provincial People's Hospital; Guangdong General Hospital and Guangdong Academy of Medical Sciences

Suggest a correctionDownload the data